Leucovorin

Calcium Folinate Pentahydrate, the active ingredient in Leucovorin, is a folinic acid presented as a sterile injectable solution for intramuscular and intravenous use. It is employed to mitigate toxicity from certain chemotherapy agents and to support patients with folate deficiency.

GNH USA supplies Leucovorin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leucovorin is used in clinical settings that involve folate‑antagonist chemotherapy and folate deficiency. - High‑dose methotrexate therapy: provides rescue to reduce life‑threatening toxicity. - Fluoropyrimidine chemotherapy (e.g., 5‑FU, capecitabine): decreases mucosal and hematologic toxicity. - Folate deficiency: supplies reduced folate for patients unable to convert folic acid. - Certain hematologic disorders: supports bone‑marrow recovery during intensive treatment.

Leucovorin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea or vomiting - Flushing or warmth sensation - Low-grade fever - Mild hypotension - Transient rash or itching

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Acute renal impairment - Severe hypotension requiring intervention - Hemolytic anemia in susceptible individuals

Leucovorin should be administered with careful clinical monitoring. - Renal function assessment: evaluate creatinine clearance before dosing. - Electrolyte monitoring: watch for changes in potassium and magnesium. - Hypersensitivity: discontinue if signs of severe allergic reaction appear. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Hepatic impairment: consider dose adjustment in severe liver disease. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Leucovorin may interact with other drugs affecting folate metabolism or renal function.

Major Interactions (Avoid): - Concurrent high‑dose antifolate agents (e.g., pemetrexed) that may negate rescue effect. - Nephrotoxic drugs (e.g., aminoglycosides) that increase risk of renal injury.

Moderate Interactions (Monitor Closely): - Fluoropyrimidines (5‑FU, capecitabine): monitor for enhanced toxicity. - Cytarabine: observe for additive myelosuppression. - Cisplatin: assess renal function closely. - Warfarin: folate may affect INR, require more frequent monitoring.